DAX23.411 -0,8%Est505.705 -0,8%MSCI World4.343 -0,1%Top 10 Crypto9,5700 +4,9%Nas22.162 -0,7%Bitcoin62.650 +2,3%Euro1,1447 -0,6%Öl101,7 -0,1%Gold5.036 -1,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 Lufthansa 823212 Siemens Energy ENER6Y Deutsche Bank 514000 NVIDIA 918422 SAP 716460 DroneShield A2DMAA Allianz 840400 Deutsche Telekom 555750 BASF BASF11 TUI TUAG50 BioNTech (ADRs) A2PSR2 Volkswagen (VW) vz. 766403 Zalando ZAL111 RENK RENK73
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Iran-Krieg und Zinssorgen: DAX volatil -- US-Börsen fester -- Adobe sucht neuen Chef -- BioNTech, Zalando, Shell, BP, Porsche, Rüstungsaktien, Bitcoin & Co. im Fokus
Top News
Ulta Beauty-Aktie bricht ein: Prognose für das Umsatzwachstum in diesem Jahr enttäuscht Ulta Beauty-Aktie bricht ein: Prognose für das Umsatzwachstum in diesem Jahr enttäuscht
Google-Aktie stabil: Gericht verlangt deutlichere Kennzeichnung von Werbung auf YouTube Google-Aktie stabil: Gericht verlangt deutlichere Kennzeichnung von Werbung auf YouTube
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Apellis Pharmaceuticals Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
16,07 EUR +0,19 EUR +1,18 %
STU
18,42 USD +0,03 USD +0,16 %
BTT
finanzen.net zero
Apellis Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.2,05 Mrd. EUR

KGV145,71Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2JAAW

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS03753U1060

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolAPLS

Apellis Pharmaceuticals Aktien News

DatumMeistgelesen
BenzingaAssessing Apellis Pharmaceuticals: Insights From 11 Financial Analysts
ZacksApellis Pharmaceuticals (APLS) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
ZacksApellis Pharmaceuticals, Inc. (APLS) Surpasses Q4 Earnings and Revenue Estimates
Wer­bungApellis Pharmaceuticals-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
BenzingaApellis Pharmaceuticals Earnings Report: Q4 Overview
ZacksEarnings Preview: Apellis Pharmaceuticals, Inc. (APLS) Q4 Earnings Expected to Decline
ZacksApellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains?
BenzingaForecasting The Future: 9 Analyst Projections For Apellis Pharmaceuticals
ZacksApellis Pharmaceuticals (APLS) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
ZacksApellis Pharmaceuticals, Inc. (APLS) Q3 Earnings and Revenues Top Estimates
ZacksApellis Pharmaceuticals, Inc. (APLS) Reports Next Week: Wall Street Expects Earnings Growth
BenzingaExpert Outlook: Apellis Pharmaceuticals Through The Eyes Of 11 Analysts
Benzinga12 Analysts Assess Apellis Pharmaceuticals: What You Need To Know
ZacksApellis Pharmaceuticals (APLS) Reports Q2 Earnings: What Key Metrics Have to Say
BenzingaApellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings)
BenzingaWhat 13 Analyst Ratings Have To Say About Apellis Pharmaceuticals
ZacksWhy Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report?
BenzingaExpert Outlook: Apellis Pharmaceuticals Through The Eyes Of 17 Analysts
MotleyFoolWhy Apellis Pharmaceuticals Wilted on Wednesday
ZacksApellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say
ZacksApellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates
ZacksApellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
BenzingaWhat 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals
BenzingaFDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals
PR NewswireSobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN
PR NewswireAPLS Investors Have Opportunity to Lead Apellis Pharmaceuticals, Inc. Securities Fraud Lawsuit
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS
PR NewswireAPELLIS PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. ...
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS
PR NewswireAPELLIS PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. ...
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS
PR NewswireSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 - (NASDAQ: APLS)
PR NewswireAPLS SHAREHOLDER ALERT: Jakubowitz Law Reminds Apellis Shareholders of a Lead Plaintiff Deadline of October 2, 2023
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS
PR NewswireAPLS LAWSUIT ALERT: Levi & Korsinsky Notifies Apellis Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
PR NewswireROSEN, A TOP RANKED LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - APLS
PR NewswireAPLS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 2, 2023 in the Class Action Filed on Behalf of Apellis Pharmaceuticals, Inc. Shareholders
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS
PR NewswireROSEN, NATIONAL INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - APLS

Apellis Pharmaceuticals News

Apellis Pharmaceuticals News: auf dieser Seite finden Sie alle Apellis Pharmaceuticals News und Nachrichten zur Apellis Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Apellis Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Apellis Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.